Amneal Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AMRX and other ETFs, options, and stocks.

About AMRX

Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. Its product portfolio includes generics, specialty, biosciences, and product catalog. 

CEO
Chintu Patel
CEOChintu Patel
Employees
8,500
Employees8,500
Headquarters
Bridgewater, New Jersey
HeadquartersBridgewater, New Jersey
Founded
2002
Founded2002
Employees
8,500
Employees8,500

AMRX Key Statistics

Market cap
6.07B
Market cap6.07B
Price-Earnings ratio
38.99
Price-Earnings ratio38.99
Dividend yield
Dividend yield
Average volume
1.90M
Average volume1.90M
High today
$19.20
High today$19.20
Low today
$18.21
Low today$18.21
Open price
$19.01
Open price$19.01
Volume
2.13M
Volume2.13M
52 Week high
$19.26
52 Week high$19.26
52 Week low
$7.80
52 Week low$7.80

Stock Snapshot

Amneal Pharmaceuticals(AMRX) stock is priced at $18.48, giving the company a market capitalization of 6.07B. It carries a P/E multiple of 38.99.

During the trading session on 2026-08-04, Amneal Pharmaceuticals(AMRX) shares reached a daily high of $19.20 and a low of $18.21. At a current price of $18.48, the stock is +1.5% higher than the low and still -3.7% under the high.

Trading activity shows a volume of 2.13M, compared to an average daily volume of 1.9M.

The stock's 52-week range extends from a low of $7.80 to a high of $19.26.

The stock's 52-week range extends from a low of $7.80 to a high of $19.26.

AMRX News

TipRanks 14h
Amneal Pharmaceuticals price target raised to $25 from $23 at UBS

UBS analyst Ashwani Verma raised the firm’s price target on Amneal Pharmaceuticals (AMRX) to $25 from $23 and keeps a Buy rating on the shares. Amneal’s strong...

Investing.com 1d
UBS raises Amneal Pharmaceuticals price target on biosimilar growth - Investing.com

...

UBS raises Amneal Pharmaceuticals price target on biosimilar growth - Investing.com
Simply Wall St 2d
Did Strong Q2 Results and Higher 2026 Revenue Guidance Just Shift Amneal Pharmaceuticals' Investment Narrative?

In late July 2026, Amneal Pharmaceuticals reported past second-quarter results showing sales of US$796.2 million and net income of US$57.66 million, alongside h...

Did Strong Q2 Results and Higher 2026 Revenue Guidance Just Shift Amneal Pharmaceuticals' Investment Narrative?

Analyst ratings

83%

of 6 ratings
Buy
83.3%
Hold
16.7%
Sell
0%

More AMRX News

Simply Wall St 3d
Amneal Stock Looks Fairly Valued Following Raised 2026 Guidance

Amneal Pharmaceuticals stock has delivered a very strong 345.7% return over the past 3 years, yet its valuation checks lean more on the expensive side rather th...

Amneal Stock Looks Fairly Valued Following Raised 2026 Guidance
TipRanks 3d
Amneal Pharmaceuticals’ Earnings Call Signals Strong Growth

Amneal Pharma ((AMRX)) has held its Q2 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock powerful investing tools with T...

TipRanks 4d
Amneal Stockholders Approve Kashiv BioSciences Acquisition Plans

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

The Motley Fool 5d
Amneal Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. Thursday, July 30, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Head of Investor Relations - Anthony DiMeo Co-Founder and Co-Chief Exe...

Amneal Q2 2026 Earnings Call Transcript
TipRanks 6d
Amneal Raises 2026 Outlook After Strong Q2 Results

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

Nasdaq 6d
Amneal Pharmaceuticals, Inc. Q2 Profit Advances

(RTTNews) - Amneal Pharmaceuticals, Inc. (AMRX) released earnings for its second quarter that Increases, from last year The company's bottom line came in at $5...

Amneal Pharmaceuticals, Inc. Q2 Profit Advances
Simply Wall St 6d
Amneal Pharmaceuticals Wins FDA Nod For Iohexol, Is The Upside Already Priced In?

Amneal Pharmaceuticals (AMRX) has drawn fresh attention after receiving U.S. Food and Drug Administration approval for additional strengths and vial sizes of it...

Amneal Pharmaceuticals Wins FDA Nod For Iohexol, Is The Upside Already Priced In?

People also own

Based on the portfolios of people who own AMRX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.